Cytokinetics to Present Non-Clinical Data Relating to CK-2017357 at the 5th Cachexia Conference
© Marketwire 2009
30.11.2009 13:41:50
|
|
non-clinical data regarding CK-2017357, a fast skeletal troponin activator,
are scheduled to be presented at the 5th Cachexia Conference, organized by
the Society on Cachexia and Wasting Disorders, being held December 5-8,
2009 at the Princesa Sofia Hotel in Barcelona, Spain.
In June 2009, Cytokinetics announced that it had initiated a
first-time-in-humans Phase I clinical trial of CK-2017357 in healthy male
volunteers. The first part, or "Part A," of this trial is designed to
assess the safety, tolerability, and pharmacokinetic profile of this drug
candidate and to determine its maximum tolerated dose and plasma
concentration, and is on-going. In November 2009, Cytokinetics announced
that the company had initiated the second part, or "Part B," of this
clinical trial. Part B is designed to evaluate the pharmacodynamic effect
of single doses that have been tolerated to date in Part A of this trial.
In November 2009, the company also announced the initiation of a second
Phase I clinical trial to investigate the safety, tolerability and
pharmacokinetic profile of
CK-2017357 after multiple oral doses to steady state in healthy male
volunteers.
CK-2017357 is a fast skeletal muscle troponin activator and is the lead
drug candidate from the company's skeletal sarcomere activator program.
CK-2017357 selectively activates the fast skeletal troponin complex and
increases its sensitivity to calcium, leading to an increase in skeletal
muscle force. This mechanism of action has demonstrated encouraging
pharmacological activity in preclinical models that may relate to the
potential treatment of diseases associated with aging, muscle wasting or
neuromuscular dysfunction.
Oral Presentation
Session #14: "Direct Activation of the Skeletal Sarcomere by the Troponin
Activator, CK-2017357, a Novel Approach to Improving Skeletal Muscle
Function" is scheduled to be presented in the I-Clinical Track - Clinical
Trials: Late Breaking Approaches, on Monday, December 7, from 11:00 AM -
11:30 AM Central European Time. The presentation will be made by Fady
Malik, MD, PhD, FACC, Vice President, Biology and Therapeutics,
Cytokinetics, Inc., South San Francisco, California.
Poster Presentation
The abstract titled, "The Fast Skeletal Troponin Activator, CK-2017357,
Increases Skeletal Muscle Force in-vitro and in-situ" is scheduled to be
displayed as a poster presentation on December 6, 2009 - December 7, 2009
during the Poster Sessions.
About Cytokinetics
Cytokinetics is a clinical-stage biopharmaceutical company focused on the
discovery and development of small molecule therapeutics that modulate
muscle function for the potential treatment of serious diseases and medical
conditions. Cytokinetics' lead drug candidate from its cardiac muscle
contractility program, omecamtiv mecarbil (formerly CK-1827452), is in
Phase II clinical development for the potential treatment of heart failure.
Amgen Inc. holds an exclusive license worldwide (excluding Japan) to
develop and commercialize omecamtiv mecarbil and related compounds, subject
to Cytokinetics' specified development and commercialization participation
rights. Cytokinetics is independently developing CK-2017357, a skeletal
muscle activator, as a potential treatment for diseases and conditions
associated with aging, muscle wasting or neuromuscular dysfunction.
CK-2017357 is in Phase I clinical development. Cytokinetics is also
conducting non-clinical development of compounds that inhibit smooth muscle
contractility and which may be useful as potential treatments for diseases
and conditions such as systemic hypertension, pulmonary arterial
hypertension or bronchoconstriction. In addition, prior Cytokinetics'
research generated three anti-cancer drug candidates in Phase I clinical
development: ispinesib, SB-743921 and GSK-923295. Cytokinetics is seeking a
partner for ispinesib and SB-743921. GSK-923295 is being developed by
GlaxoSmithKline in collaboration with Cytokinetics. All of these drug
candidates and potential drug candidates have arisen from Cytokinetics'
research activities and are directed towards the cytoskeleton. The
cytoskeleton is a complex biological infrastructure that plays a
fundamental role within every human cell. Additional information about
Cytokinetics can be obtained at www.cytokinetics.com : www.cytokinetics.com .
This press release contains forward-looking statements for purposes of the
Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics
disclaims any intent or obligation to update these forward-looking
statements, and claims the protection of the Act's safe harbor for
forward-looking statements. Examples of such statements include, but are
not limited to, statements relating to planned presentations, Cytokinetics'
clinical trials for CK-2017357, and the properties and potential benefits
of Cytokinetics' drug candidates and potential drug candidates. Such
statements are based on management's current expectations, but actual
results may differ materially due to various risks and uncertainties,
including, but not limited to, potential difficulties or delays in the
development, testing, regulatory approval and production of Cytokinetics'
drug candidates and potential drug candidates that could slow or prevent
clinical development or product approval, including risks that current and
past results of clinical trials or preclinical studies may not be
indicative of future clinical trials results and that Cytokinetics' drug
candidates and potential drug candidates may have unexpected adverse side
effects or inadequate therapeutic efficacy. For further information
regarding these and other risks related to Cytokinetics' business,
investors should consult Cytokinetics' filings with the Securities and
Exchange Commission.
Contacts:
Cytokinetics, Incorporated
Christopher S. Keenan
(Investors and Media)
Director, Investor Relations
(650) 624-3000
